Gan and Lee Pharmaceuticals, USA
Quick facts
Phase 3 pipeline
- Gan & Lee Insulin Glargine Injection · Diabetes
Insulin glargine is a long-acting basal insulin that binds to insulin receptors to lower blood glucose by promoting glucose uptake and storage in peripheral tissues and suppressing hepatic glucose production. - GZR4 Injection · Diabetes
GZR4 Injection is a glucagon receptor antagonist.
Phase 1 pipeline
- Gan & Lee Insulin Aspart
- Gan & Lee insulin glargine followed by Lantus
- GLR2007
- GZR-18
- GZR-33
- GZR18 and metformin
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Gan and Lee Pharmaceuticals, USA portfolio CI brief
- Gan and Lee Pharmaceuticals, USA pipeline updates RSS
Frequently asked questions about Gan and Lee Pharmaceuticals, USA
What is Gan and Lee Pharmaceuticals, USA's pipeline?
Gan and Lee Pharmaceuticals, USA has 2 drugs in Phase 3, 0 in Phase 2, 6 in Phase 1. Late-stage candidates include Gan & Lee Insulin Glargine Injection, GZR4 Injection.
Related
- Sector hub: All tracked pharma companies